Before menopause · one approved use
PT-141 for Women has one limited approval
Desire improved slightly. The studies didn't show a large gain for most women.
A surprise effect led to studies in women
The drug's makers began with a medicine meant to darken skin. An unplanned sexual response made them study that effect on its own. Later work focused on women whom stubborn low desire deeply troubled.
Only some women fit the PT-141 for women approval. They must still have periods. Their lasting lack of sexual interest must also cause deep personal distress [6]. Approval excludes those past menopause.
Large studies saw modestly higher desire and lower distress [3]. A brain scan found higher desire scores through the day [5]. In longer follow-up, about four people in ten had nausea [4]. You need both sides of that result.
PT-141 is FDA-approved for one limited use
Bremelanotide was approved on June 21, 2019. The approval covers a shot for certain women before menopause [6]. Their lasting low desire must cause deep distress. The shot goes into the fat below the skin.
Men aren't covered. Women past menopause and people seeking help with erections aren't covered either [6]. Broad claims about better sexual performance go beyond the approval. Ads often cross that line.
“PT-141 research chemical” means lab material, not approved medicine. It lacks checks to confirm the named drug, its cleanliness, and its strength [6]. A matching name on the package proves little. The powder inside may be different.
A rat study came before the studies in women
In 2004, researchers gave the drug to female rats. The rats sought mating more often after the drug. They moved as usual, and their simple body reflexes didn't change [2]. The result pointed to sexual interest rather than general movement.
Researchers called it the first drug to prompt that kind of interest [2]. But rats can't tell women how they will feel. The animal study raised a question. It did not answer the question for patients.
Later Phase 3 work measured women's desire and their distress [3]. It didn't test better blood flow. The rat work set the topic. Only the studies in women could test for real help.
PT-141 raised desire by a modest amount
Women rated their desire a little higher. They also felt a little less troubled by low desire [3]. Scans showed a different brain response, not greater blood flow. Desire scores stayed higher for up to 24 hours [5].
The drug's 2.7-hour half-life means its amount in blood fell by half in that time [5][6]. The drug wasn't all gone then. The reported effect lasted longer than that first fall. The 24 hours don't promise your timing.
A follow-up look at women's own survey answers found some help [7]. The main studies still found unwanted effects, led by nausea. A 2025 meeting report also noted gains in arousal and orgasm [11]. Approval still leaves out women past menopause and concerns other than lasting low desire [6].
PT-141 worked, but the average change was small
Two Phase 3 studies found a modest edge over placebo. Women rated their desire a bit higher with the drug. Question 13 asked how upset low desire made them. The result carried a figure below .001; chance alone was an unlikely cause [3].
A 52-week follow-up found that the desire gain lasted [4]. That sounds good until you ask how much women felt it. Other experts asked the same question. Sales pages rarely lead with their answer.
Those reviews called the effect small. They doubted that the average change mattered much in daily life [8][9]. The fair verdict is modest benefit, not a dramatic change. That limited size matters beside the nausea.
FDA instructions set firm limits
These are FDA rules, not a personal amount. For lasting low desire, the approved amount is 1.75 mg by a when-needed shot into fat below the skin. The shot is at least 45 minutes before sex. The limit is one dose within 24 hours and no more than 8 each month [6].
Earlier Phase 2 work was the middle round of testing. It tried 0.75, 1.25, and 1.75 mg [6]. Researchers chose 1.75 mg for the later studies. Those figures describe research, not your care.
The PT-141 dosage for women follows an FDA limit
The approved amount is 1.75 mg as a when-needed shot into the fat layer. FDA instructions repeat 45 minutes of lead time, one dose in 24 hours, and no more than 8 each month [6]. Your doctor sets your care; this page doesn't. Lab material isn't an approved drug [6].
PT-141 is not the daily pill or a hormone
These treatments aren't the same. Bremelanotide is a when-needed shot that starts in the brain. Flibanserin is an approved pill taken every day by certain women whose low desire lasts. By contrast, testosterone is a hormone some doctors use for women's sexual concerns, though FDA approval doesn't cover that purpose [6].
At a 2025 meeting, researchers compared bremelanotide, flibanserin, and testosterone [15]. The report found different results among the three treatments. It didn't name one best choice for every woman. Any claim of a clear winner would go too far.
The useful question is which facts fit the woman. A daily pill, a when-needed shot, and a hormone carry different proof and harms. Your doctor can weigh those facts against your health. Ask what makes one choice safer than another.